

Helseeffekter av oksidert fiskeolje. En intervensjonsstudie på friske personer.



Inger Ottestad
Stipendiat
Høgskolen i Oslo og Akershus/
Universitetet i Oslo




Outline of the presentation

- introduction
- design and analysis
- results
- discussion
- conclusion



Background

- n-3 protect against CVD
 - n-3 are susceptible for oxidation
 - Oxidation products in omega-3 supplements
 - Oxidized vegetable oil increase lipid peroxides
 - Data on intake of oxidized fish oil not available
- 



A close-up photograph of several yellow, oval-shaped capsules, likely containing cod liver oil, resting on a light-colored surface. The capsules are slightly out of focus, with the one in the foreground being sharper.

Aim of the study

To investigate markers of

- lipid oxidation
- oxidative stress
- inflammation

in healthy humans after daily intake of oxidized cod liver oil for 3 and 7 weeks

Study protocol

Inclusion criteria:

- Healthy, none smokers men and women 18-50 years
- CRP < 10 mg/L
- Tot-chol < 7.5 mmol/L, triglycerides < 4.5 mmol/L
- Blood pressure (\leq 160/110 mmHg)
- Normal serum level of: glucose, insulin, TSH, T3 and T4
- BMI < 30 kg/m²
- Willing to avoid fish, fish products, dietary supplements and omega-3 enriched food during the study period
- Willing to take 16 capsules/day for 7 weeks




Ethics:

Appoved by Regional Committee of Medical Ethics
and by the Norwegian Social Science Data Service
Registered at www.clinicaltrial.gov

Study design:

- Double-blinded, randomized controlled trial
- Stratified by gender
- Capsule compleance < 70% → exclusion

Study design



Lipid oxidation products and fatty acids were measured in food and capsules



Content of volatile oxidation products were analyzed by Dynamic headspace/GC-MS

Fatty acid composition and lipid oxidation products in the intervention oils

	Cod liver oil ₁	Oxidized Cod liver oil ₁	High oleic sunflower oil
<i>Fatty acids:</i>			
SFA (g/100g)	16	16	7
MUFA (g/100g)	47	46	76
PUFA (g/100g)	28	28	9
EPA (C20:5, n-3) (g/100g)	9.0	9.1	0
DHA (C22:6, n-3) (g/100g)	11.1	11.2	0
DPA (C22:5, n-3) (g/100g)	1.1	1.1	0
ALA (C18:3, n-3) (g/100g)	0.8	0.8	0.3
<i>Oxidation level:</i>			
PV (mekv/kg)	4	18	4
AV	3	9	3

¹ Cod liver oil (*Gadidae sp.*) was provided from TINE SA (Norway)

PV and AV were measured using methods according to AOCS Official Method Cd 8-53 and Cd 18-90, respectively.

Markers measured in this study

Markers	Compartment	Methods
8-iso-PGF _{2α}	Urine spot	LC/MS/MS (Vitas)
4-HHE	Plasma	GC/MS (Nofima)
4-HNE	Plasma	GC/MS (Nofima)
α-tocoferol	Plasma	HPLC (Nofima)
Fatty acids	Plasma	GC (Nofima)
Glutathione (tGSH)	RBC	Bio Rad kit (Vitas)
Glutathione peroxidase (GPx)	RBC	Spectrophotom. Assay (Denmark)
Glutathione transferase (GR)	RBC	Spectrophotom. Assay (Denmark)
Catalase	RBC	Spectrophotom. Assay (Denmark)
hsCRP	Serum	Routine lab (Furst)
Lipids (t-chol, LDL, HDL, TG) Liver markers: AST, ALT, G-GT,ALP	Serum	Routine lab (Furst)

Results



Baseline characteristics

	CLO	Ox CLO	HOSO	P
Male/Female (n)	5 /12	5 /13	5 /14	
Age (y)	25 (23-32)	22 (21-28)	25 (22-31)	0.32
BMI (kg/m ²)	22.1 ± 2.5	22.2 ± 1.7	23.5 ± 3.1	0.20
TC (mmo/L)	4.6 ± 0.8	4.7 ± 0.9	4.9 ± 0.8	0.57
LDL-C (mmol/L)	2.5 ± 0.8	2.7 ± 0.8	2.7 ± 0.6	0.63
HDL-C (mmol/L)	1.5 ± 0.3	1.4 ± 0.4	1.5 ± 0.4	0.88
TG (mmol/L)	0.8 (0.7-0.9)	0.9 (0.5-1.5)	1.0 (0.4-5.0)	0.77
Glucose (mmol/L)	4.6 ± 0.3	4.8 ± 0.4	4.8 ± 0.5	0.27
AST (U/L)	22 ± 5	21 ± 5	21 ± 4	0.61
ALT (U/L)	20 ± 7	20 ± 13	21 ± 7	0.61
G-GT (U/L)	21 ± 14	16 ± 7	17 ± 8	0.30
ALP (U/L)	69 ± 20	62 ± 23	59 ± 14	0.30

At baseline, no significant difference between the randomization groups was observed

Plasma fatty acids


Variables	CLO		Ox CLO		HOSO		P
	Baseline	End of study	Baseline	End of study	Baseline	End of study	
Fatty acids (%wt)							
18:2n-6 (LA)	32.7 ± 3.4	29.3 ± 4.4	28.2 ± 4.5	28.0 ± 2.6	28.9 ± 5.0	29.1 ± 3.8	0.01
20:4n-6 (AA)	6.3 ± 1.1	5.7 ± 0.8	6.3 ± 1.0	5.7 ± 0.8	6.2 ± 1.7	6.4 ± 1.4	0.02
18:3n-3 (ALA)	0.6 ± 0.2	0.5 ± 0.1	0.6 ± 0.2	0.5 ± 0.1	0.6 ± 0.2	0.5 ± 0.1	0.98
20:5n-3 (EPA)	0.7 ± 0.2	2.5 ± 0.8	0.6 ± 0.3	2.6 ± 1.0	0.6 ± 0.2	0.7 ± 0.3	<0.001
22:5n-3 (DPA)	0.5 ± 0.1	0.7 ± 0.2	0.5 ± 0.1	0.7 ± 0.1	0.5 ± 0.1	0.5 ± 0.1	<0.001
22:6n-3 (DHA)	2.2 ± 0.5	3.8 ± 0.9	2.0 ± 0.6	3.9 ± 0.8	2.2 ± 0.5	2.2 ± 0.5	<0.001

No difference between the CLO groups at baseline or after 3 and 7 wk.

Markers of lipid peroxidation, oxidative stress and inflammation

Variables	CLO		Ox CLO		HOSO		P
<i>Plasma:</i>	Baseline	End of study	Baseline	End of study	Baseline	End of study	
4-HHE(ng/ml)	3.0 (1.6-3.8)	2.2 (1.6-3.6)	3.7 (1.9-5.0)	3.1 (1.9-5.1)	4.3 (1.6-5.5)	3.5 (2.1-4.8)	0.54
4-HNE(ng/ml)	3.4 (2.4-2.2)	3.3 (2.7-4.5)	4.4 (3.7-4.2)	4.3 (1.3-4.9)	3.9 (2.6-6.3)	3.3 (2.3-4.3)	0.47
α -tocopherol/total lipids	4.0 (3.6-4.6)	4.0 (3.6-4.5)	4.0 (3.5-4.3)	4.0 (3.5-4.3)	3.9 (3.7-4.2)	4.1 (3.7-4.3)	0.67
<i>Serum:</i>							
Serum-hsCRP (mg/L)	0.5 (0.2-1.2)	0.8 (0.2-1.3)	0.6 (0.3-1.4)	0.7 (0.3-1.7)	1.0 (0.5-2.7)	1.2 (0.6-3.1)	0.68
<i>Urine:</i>							
8-iso-PGF-2 α pg/mg creatinine	288 (225-339)	239 (156-320)	280 (194-381)	248 (171-307)	237 (149-360)	280 (103-414)	0.15
<i>Erythrocytes:</i>							
Glutathione (mM)	1.3 (1.0-1.7)	1.4 (1.1-1.6)	1.5 (1.3-1.7)	1.7 (1.4-2.0)	1.6 (1.2-1.7)	1.3 (1.2-1.9)	0.44
GR U/g (Hb)	7.3 (6.8-8.6)	7.5 (6.8-8.5)	8.2 (7.4-9.0)	8.2 (7.1-8.5)	7.8 (7.2-9.2)	8.1 (7.5-8.8)	0.58
GPx U/g (Hb)	120 (115-124)	118 (114-126)	110 (105-124)	109 (96-121)	113 (101-122)	111 (103-120)	0.54
CAT U/g (Hb)	10.3 (9.2-10.6)	9.6 (9.1-10.1)	9.3 (8.5-10.7)	9.6 (8.7-10.0)	10.1 (9.2-10.4)	9.4 (9.2-10.3)	0.70

Data are presented as mean (\pm SD) or median (25,75 percentiles) when not normally distributed
 After 3 and 7 wk of intervention, no significant differences between the randomization groups were observed

A close-up photograph of several golden, oval-shaped capsules or pills arranged in a row. The capsules are highly reflective, showing bright highlights and deep shadows. The word "Discussion" is overlaid in the center in a white, sans-serif font.

Discussion

A close-up photograph of several yellow, oval-shaped capsules, likely containing a liquid or soft gel, resting on a light-colored surface. The capsules are arranged in a slightly curved line, with the foreground ones in sharp focus and the background ones blurred.

Compliance

- High compliance (> 95 %)

Experience

- Rate of side effects identical
- No drop out
- Difficult to distinguish the quality

A close-up photograph of several yellow, oval-shaped capsules or pills, some in focus and others blurred in the background, set against a light blue-grey background. The capsules are arranged in a diagonal line from the top left towards the bottom right.

Limitations

- Sample size
- Short term study

Strengths

- Study design
- High compliance
- Cod liver oil taken from one batch
- Specific and sensitive methods

A close-up photograph of several golden, oval-shaped capsules or pills arranged in a row. The capsules are highly reflective, showing bright highlights and deep shadows. The word "Conclusion" is overlaid in the center in a clean, white, sans-serif font. The background is a soft, out-of-focus golden glow, suggesting a shallow depth of field.

Conclusion



Konklusjon

I friske personer,
inntak av oksidert tran oil for 3 and 7 uker
påvirket ikke markører for:

- oksidativt stress
- lipid peroksidering
- inflammasjon

EPA and DHA øker like mye i gruppene som fikk
tran av ulik kvalitet.



Konklusjon

- I lys av de markørene vi har benyttet, så finner ingen negative effekter av oksidert tran
- Oksidert tran påvirker ikke opptak av n-3
- Med tanke på studiens varighet, størrelse og at den er gjort på friske personer, så bør en slik studie gjentas før man kan trekke endelige konklusjoner

1 **Oxidised fish oil does not influence established markers of oxidative**
2 **stress in healthy human subjects: a randomised controlled trial**

3 Inger Ottestad^{1,2}, Gjermund Vogt³, Kjetil Retterstøl⁴, Mari C. Myhrstad¹, John-Erik Haugen³,
4 Astrid Nilsson³, Gitte Ravn-Haren⁵, Berit Nordvi⁶, Kirsti W. Brønner⁶, Lene F. Andersen²,
5 Kirsten B. Holven² and Stine Marie Ulven^{1*}

6 ¹*Faculty of Health, Nutrition and Management, Akershus University College, PO Box 423, 2001 Lillestrøm, Norway*

7 ²*Department of Nutrition, Institute for Basic Medical Sciences, University of Oslo, PO Box 1046, Blindern, 0317 Oslo,*
8 *Norway*

9 ³*Nofima Mat AS, Ostloveien 1, 1430 Ås, Norway*

10 ⁴*Lipid Clinic, Medical Department, Rikshospitalet-Oslo University Hospital, PO Box 4950, Nydalen, 0424 Oslo, Norway*

11 ⁵*Department of Toxicology and Risk Assessment, Technical University of Denmark, National Food Institute,*
12 *Mørkhøj Bygade 19, 2860 Søborg, Denmark*

13 ⁶*TINE SA, Centre for Research and Development, PO Box 7, Kalbakken, N-0902 Oslo, Norway*

14 *(Received 3 June 2011 – Revised 7 September 2011 – Accepted 8 September 2011)*

A row of several yellow, oval-shaped capsules is arranged diagonally across the top half of the slide. They are set against a white background with soft shadows cast beneath them.

Thanks to my supervisors and collaboration partners

Akershus University College
Stine Ulven, Mari Myhrstad

University of Oslo, Department of Nutrition
Kirsten Holven, Lene Frost Andersen; Kjetil Retterstøl

Nofima Mat AS
Gjermund Vogt, John Erik Hugen, Astrid Nilsson

Lipid Clinic, Rikshospitalet-Oslo University Hospital
Kjetil Retterstøl

Division of Toxicology and Risk Assessment, DTU Food, Denmark
Gitte Ravn-Haren

TINE BA R&D Center
Kirsti Wettre-Brønner, Berit Nordvi

Funding: Norwegian Research Council and TINE



Takk for meg!